Protective effect and mechanism of silybin on islet β-cells

Abstract

Abstract: A flavonoid extracted of milk thistle, silybin, is the most prescribed natural compounds, which is increasingly used in many kinds of diseases. Recent experimental studies have clearly demonstrated the effects of silybin on islets, its antioxidant, anti-inflammatory effects, and its effect of improving glucoliptoxicity, as well as its protective effect of improving insulin sensitivity and ameliorating insulin resistance. Therefore silybin seems a promising drug for diabetes mellitus.

Key words: Silybin, Insulin-secreting cells, Diabetes mellitus

CLC Number:

R587

XU Jun, MO Zhao-hui. Protective effect and mechanism of silybin on islet β-cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 476-480.

References

[1] Loguercio C, Festi D.Silybin and the liver: from basic research to clinical practice[J].World J Gastroenterol,2011,17(18):2288-2301.
[2] Gazák R, Walterová D, Kren V.Silybin and silymarin——new and emerging applications in medicine[J].Curr Med Chem,2007,14(3):315-338.
[3] Soto CP,Perez BL,Favari LP,et al. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin[J].Comp Biochem Physiol C,1998,119(2):125-129.
[4] Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes[J]. Diabetologia,2008,51(2):216-226.
[5] Soto C,Mena R,Luna J,et al. Silymarin induces recovery of pancreatic function after alloxan damage in rats [J].Life Sci,2004,75(18):2167-2180.
[6] Huseini HF,Larijani B, Heshmat R,et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial[J].Phytother Res,2006,20(12):1036-1039.
[7] Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes[J].J Med Food,2007,10(3):543-547.
[8] Trouillas P,Marsal P,Svobodová A,et al. Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study[J].J Phys Chem A,2008,112(5): 1054-1063.
[9] Comoglio A,Tomasi A,Malandrino S,et al. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals[J].Biochem Pharmacol,1995,50(8):1313-1316.
[10] Fu H,Katsumura Y,Lin M,et al. Fast repair activities towards dGMP hydroxyl radical adducts by silybin and its analogues[J].J Radiat Res,2008,49(6): 609-614.
[11] Täger M,Dietzmann J, Thiel U,et al. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin[J].Free Radic Res,2001,34(2):137-151.
[12] Soto C,Recoba R,Barrón H,et al. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas[J].Comp Biochem Physiol C,2003,136(3):205-212.
[13] Tong S,Chu C,Wei Y,et al. Preparation and effects of 2,3-dehydrosilymarin, a promising and potent antioxidant and free radical scavenger[J].J Pharm Pharmacol,2011,63(2):238-244.
[14] Abdelli S,Abderrahmani A,Hering BJ,et al. The c-Jun N-terminal kinase JNK participates in cytokine- and isolation stress-induced rat pancreatic islet apoptosis[J].Diabetologia,2007,50(8):1660-1669.
[15] Kim WH,Lee JW,Gao B,et al. Synergistic activation of JNK/SAPK induced by TNF-alpha and IFN-gamma: apoptosis of pancreatic beta-cells via the p53 and ROS pathway[J].Cell Signal,2005,17(12):1516-1532.
[16] Matsuda T,Ferreri K,Todorov I,et al. Silymarin protects pancreatic β-cells against cytokine-mediated toxicity: Implication of c-Jun NH2-terminal kinase and Janus kinase/signal transducer and activator of transcription pathways[J].Endocrinology,2005,146(1):175-185.
[17] Kang JS,Jeon YJ,Park SK,et al. Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1β and prostaglandin E2 synthesis by silymarin[J].Biochem Pharmacol,2004,67(1):175-181.
[18] Cho JY,Kim PS,Park J,et al. Inhibitor of tumor necrosis factor-α production in lipopolysaccharide-stimulated RAW264.7 cells from Amorpha fruticosa[J].J Ethnopharmacol,2000,70(2):127-133.
[19] Azevedo-Martins AK,Lortz S,Lenzen S,et al. Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-kappaB activation in insulin-producing cells[J].Diabetes,2003,52(1):93-101.
[20] van Raalte DH, Diamant M. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy[J].Diabetes Res Clin Pract,2011,93 (Suppl 1):S37-46.
[21] Cnop M. Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes[J].Biochem Soc Trans,2008,36(3):348-352.
[22] Poitout V,Amyot J,Semache M,et al. Glucolipotoxicity of the pancreatic beta cell[J].Biochimica Biophysica Acta,2010,1801(3):289-298.
[23] Unger RH, Clark GO, Scherer PE,et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome[J].Biochim Biophys Acta,2010,1801(3):209-214.
[24] Unger RH,Zhou YT,Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin[J].Proc Natl Acad Sci USA,1999,96(5):2327-2332.
[25] Yamashita T,Eto K,Okazaki Y,et al. Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a β-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c[J].Endocrinology,2004,145(8):3566-3577.
[26] Attie D. Insig: a significant integrator of nutrient and hormonal signals[J].J Clin Invest,2004,113(8):1112-1114.
[27] McPherson R, Gauthier A. Molecular regulation of SREBP function: the Insig-SCAP connection and isoform-specific modulation of lipid synthesis[J].Biochem Cell Biol,2004,82(1):201-211.
[28] Chen K,Jin P,He HH,et al. Overexpression of Insig-1 protects β cell against glucolipotoxicity via SREBP-1c[J].J Biomed Sci,2011,18:57.
[29] Ka SO,Kim KA,Kwon KB,et al. Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway[J].Int J Mol Med,2009,23(5):633-637.
[30] Yao J,Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats[J].Braz J Med Biol Res,2011,44(7):652-659.
[31] Velussi M,Cernigoi AM,De Monte A,et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients[J].J Hepatol,1997 ,26(4):871-879.
[32] 叶建红,黎锋,李芳萍,等. 水飞蓟宾对代谢综合征患者葡萄糖代谢率与脂肪因子的影响[J].中国老年学杂志,2011,31(3):374-376.
[33] Wang Q, Liu M, Liu WW, et al. In vivo recovery effect of silibinin treatment on streptozotocin-induced diabetic mice is associated with the modulations of Sirt-1 expression and autophagy in pancreatic β-cell[J].J Asian Nat Prod Res,2012,14(5):413-423.
[34] Cheng B, Gong H, Li X, et al. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide[J].Biochem Biophys Res Commun,2012,419(3):495-499.